Mountain Group Partners spearheaded a funding round for Circular Genomics, with the active involvement of new investor UNM Rainforest Innovations and continued support from initial investors, including Cottonwood Technology Fund, Tramway Venture Partners, and undisclosed individuals.

The newly secured funds are earmarked for the development and expansion of commercial operations, gearing up for the impending launch of its clinical assay centered around circular RNA.

Circular Genomics: Pioneering Precision Medicine in Psychiatry and Neurology

Under the leadership of CEO Dr. Paul Sargeant, Circular Genomics specializes in the creation of precision medicine tools, data, and diagnostics rooted in circular RNA for psychiatry and neurology applications.

Utilizing exclusive licenses and technologies in circular RNA, the company is dedicated to addressing major depressive disorder and various neurological diseases.

The initial lineup of products includes assays designed to evaluate and customize optimal treatment protocols for individual patients, offering swift validation of treatment effectiveness within days to weeks, a notable improvement compared to the conventional months-long timeframe.

Dr. Paul Sargeant’s Perspective on the Future

Dr. Paul Sargeant expressed optimism about the company’s trajectory, stating, “We plan to launch our first test in 2024, which will predict response to SSRI antidepressants, addressing the issue of high therapy failure rates and low clinical outcomes.

Furthermore, the launch of this first assay paves the way for a set of tests covering the complete patient care continuum in major depression, and using the same circular RNA platform, in other neurological diseases too.”